Related Experiment Video
Updated: Apr 30, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Eliminating medication copayments reduces disparities in cardiovascular care
Insights
Reducing medication copayments after myocardial infarction significantly improved adherence and clinical outcomes for nonwhite patients, potentially reducing cardiovascular health disparities.
Area of Science:
- Cardiovascular Medicine
- Health Services Research
- Health Disparities
Background:
- Racial and ethnic disparities in cardiovascular care are prevalent in the U.S.
- Minority patients are less likely to receive secondary prevention therapies post-myocardial infarction.
- The effect of reduced copayments on these disparities is not well understood.
Purpose of the Study:
- To investigate the impact of reduced medication copayments on adherence and clinical outcomes.
- To determine if reduced copayments can mitigate racial and ethnic disparities in cardiovascular care.
Main Methods:
- Analysis of data from the Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) trial.
- Self-reported race and ethnicity data were used to stratify participants.
- Medication adherence, clinical outcomes, and healthcare spending were compared between groups.
Main Results:
- Full drug coverage improved medication adherence for all patients.
- Nonwhite patients experienced a 35% reduction in major vascular events or revascularization with full coverage.
- Full coverage reduced total healthcare spending by 70% for nonwhite patients, with no significant effect on white patients.
Conclusions:
- Lowering medication copayments after myocardial infarction may be an effective strategy to reduce racial and ethnic disparities.
- Financial barriers to essential medications disproportionately affect minority populations.
- Targeted financial assistance can improve cardiovascular outcomes and reduce healthcare costs in underserved groups.
Abstract:
Substantial racial and ethnic disparities in cardiovascular care persist in the United States. For example, African Americans and Hispanics with cardiovascular disease are 10-40 percent less likely than whites to receive secondary prevention therapies, such as aspirin and beta-blockers. Lowering copayments for these therapies improves outcomes among all patients who have had a myocardial infarction, but the impact of lower copayments on health disparities is unknown. Using self-reported race and ethnicity for participants in the Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) trial, we found that rates of medication adherence were significantly lower and rates of adverse clinical outcomes were significantly higher for nonwhite patients than for white patients. Providing full drug coverage increased medication adherence in both groups. Among nonwhite patients, it also reduced the rates of major vascular events or revascularization by 35 percent and reduced total health care spending by 70 percent. Providing full coverage had no effect on clinical outcomes and costs for white patients. We conclude that lowering copayments for medications after myocardial infarctions may reduce racial and ethnic disparities for cardiovascular disease.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Atherosclerosis III: Management
Heart Failure V: Medical Management
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Preventive Healthcare Services

